期刊
JOURNAL OF PHARMACOLOGICAL SCIENCES
卷 110, 期 2, 页码 169-181出版社
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1254/jphs.08293FP
关键词
inflammatory bowel disease; experimental model; SCID mice; corticosteroid; anti-tumor necrosis factor (TNF)-alpha antibody
Mouse colitis induced by transfer of CD4(+)CD45RB(high) CD25(-) cells share many pathological features with human inflammatory bowel disease (11313). However, there is little known about how Mouse colitis responds to drugs used for IBD treatment. To address this issue, we have investigated the effects of the 11313 drugs, dexamethasone and anti-tumor necrosis factor-alpha antibody, on the mouse experimental colitis. Administration of either drug ameliorated their morbid signs such as body weight loss, colon shortening, and an increased ratio between colon and body weights (C/B ratio). Also improved were mucosal inflammatory signs in the colon, and histological damage scores were significantly decreased. Of the proinflammatory cytokines assayed in colon and plasma samples from the colitis mice, the colonic interleukin (IL)-1 beta level alone was significantly decreased by either drug administration. Regression analysis of data obtained with either drug revealed a close correlation between the histological damage score and C/B ratio or colonic IL-1 beta level. The present results show that the experimental mouse colitis responds to IBD drugs with its amelioration and that the C/B ratio and colonic IL-1 beta are available as a disease marker for IBD, Suggesting the usefulness of this mouse model of colitis for pre-clinical screening of drug candidates for IBD treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据